Motus Gi Holdings, INC 8-K filings

Motus GI Holdings has announced the resignation of its entire board of directors and CEO, the appointment of a sole director, and the commencement of a wind-down of the company's business affairs.

Motus GI Holdings received a notice of default on its loan agreement due to the approval of a distribution plan.

Motus GI Holdings has approved a plan to liquidate and dissolve the company, pending stockholder approval.

Motus GI reported increased revenue and a reduced net loss in Q1 2024, alongside a successful commercial launch of their Pure-Vu system.

Motus GI Holdings is set to be delisted from the Nasdaq Capital Market after its share price remained below $1 for 30 consecutive days, and will move to the OTC Pink Market.

Motus GI announced its full year 2023 financial results, highlighted the limited commercial launch of its Pure-Vu EVS system, and discussed its ongoing pursuit of strategic partnerships.

Motus GI Holdings has amended its CFO's employment agreement to include a special adjustment payment upon termination for good reason, and has deferred board compensation and employee bonuses pending a strategic transaction.

Motus GI Holdings stockholders approved the potential issuance of up to 2,666,666 shares of common stock related to warrants issued in a prior private placement.

Motus GI Holdings has entered into an agreement for an institutional investor to exercise existing warrants for $2.7 million, while issuing new warrants and amending existing ones.

Motus GI Holdings has been granted a new U.S. patent for its Pure-Vu system's automatic self-purging feature, designed to prevent clogs during GI tract cleansing.

Motus GI Holdings has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, avoiding delisting.